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SUMMARY
The NUP214-ABL1 fusion is a constitutively activated tyrosine kinase that is significantly associated with
overexpression of the TLX1 and TLX3 transcription factors in T cell acute lymphoblastic leukemia (T-ALL).
Here we show that NUP214-ABL1 cooperates with TLX1 in driving T-ALL development using a transgenic
mouse model and human T-ALL cells. Using integrated ChIP-sequencing, ATAC-sequencing, and RNA-
sequencing data, we demonstrate that TLX1 and STAT5, the downstream effector of NUP214-ABL1, co-
bind poised enhancer regions, and cooperatively activate the expression of key proto-oncogenes such as
MYC and BCL2. Inhibition of STAT5, downregulation of TLX1 or MYC, or interference with enhancer function
through BET-inhibitor treatment leads to reduction of target gene expression and induction of leukemia
cell death.
INTRODUCTION
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive
hematological disease, which arises from the malignant trans-
formation of developing T cell progenitors due to the accumu-
lation of oncogenic aberrations (Belver and Ferrando, 2016;
Girardi et al., 2017). Although survival rates are currently close
to 90% in children, adult cases still have a poor prognosis
(Bassan and Hoelzer, 2011; Pui et al., 2015). Moreover, current
therapy is associated with both short-term and long-term side
effects, especially devastating for children (Haddy et al.,
2009). Therefore, there remains an urgent need to uncover
the molecular mechanisms underlying T-ALL in order to iden-
tify therapeutic targets and to develop personalized targeted
therapies.
T-ALL can be subdivided into clinically relevant subgroups,
based on the ectopic and mutually exclusive expression of tran-
scription factors, such as TAL1/2, LMO1/2, TLX1/3, HOXA9/10,
or NKX2-1. Each subgroup presents with different immuno-
phenotypes and gene expression patterns that reflect devel-
opmental arrest at different stages of T cell maturation (Hom-
minga et al., 2011; Van Vlierberghe et al., 2012). Furthermore,
next-generation sequencing has contributed to the discovery
of >100 genes that are recurrently mutated in T-ALL (De Keers-
maecker et al., 2013; Li et al., 2016; Liu et al., 2017; Vicente
et al., 2015).
Significance
Unraveling the molecular mechanisms underlying the cooperation between TLX1 and NUP214-ABL1/STAT5 signaling im-
proves our understanding of oncogene cooperation, and contributes to the development of effective targeted therapies.
Our data show that TLX1 and STAT5 directly cooperate at the transcriptional level through activation of enhancer regions
of key proto-oncogenes such asMYC and BCL2. Based on these findings, we demonstrate synergy between ABL1 kinase
inhibitors and BET or BCL2 inhibitors to reduce the growth of NUP214-ABL1/TLX-positive T-ALL cells in vitro and in vivo.
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Figure 1. Expression of NUP214-ABL1 and TLX1 Is Required to Induce T-ALL in a Transgenic Mouse Model
(A) Pie chart representing the percentage of T-ALL (left) or NUP214-ABL1-positive T-ALL (right) with TLX1 or TLX3 expression.
(B) Schematic overview of the transgenic mouse models used in this study. Red triangles represent LoxP sites. A conditional loxP-STOP-loxP NUP214-ABL1
knockin mouse model (abbreviated as LSL-NA) was generated. NUP214-ABL1 expression was initiated by crossing LSL-NA mice with CD4-Cre mice.
(legend continued on next page)
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TLX1 and TLX3 are not expressed in the hematopoietic system
but are ectopically expressed in approximately 30% of T-ALL
cases (Belver and Ferrando, 2016; Girardi et al., 2017). This is
the result of chromosomal translocations that place TLX1 or
TLX3 under control of regulatory elements of the T cell receptor
locus or of the BCL11B locus, respectively. Overexpression of
TLX1 in mouse T cells results in the development of T cell leuke-
mia/lymphoma with long latency, illustrating the oncogenic po-
tential of TLX1. These leukemias/lymphomas frequently harbor
inactivating mutations in Bcl11b, and were typically aneuploid
as a result of TLX1-driven defects in mitotic checkpoint activa-
tion (De Keersmaecker et al., 2010). Additional studies have
shown that TLX1 target genes show significant overlap with
NOTCH1 target genes (Durinck et al., 2015), and that TLX1 binds
to the T cell receptor alpha locus (TRA), thereby inhibiting its
recombination and blocking differentiation of the T cells (Dadi
et al., 2012). Together, these data provide first hints as to how
ectopic TLX1 expression can contribute to T-ALL development
by disturbing NOTCH1 signaling and T cell differentiation. The
role of TLX3 in T-ALL is less well studied, but Ferrando and co-
workers have shown that TLX1- or TLX3-expressing tumors
are characterized by a highly related gene expression signature
and that TLX1 and TLX3 share 75%of their direct target genes as
determined by chromatin immunoprecipitation (ChIP)-chip (Della
Gatta et al., 2012).
Besides aberrant transcription factor expression, T-ALL cases
harbor mutations that lead to constitutive activation of signaling
pathways such as the NOTCH1, PI3K-AKT, RAS-MAPK, and
IL7R-JAK-STAT pathways (Cante´-Barrett et al., 2016; Degryse
et al., 2014; Mullighan et al., 2009; Weng et al., 2004; Zenatti
et al., 2011). Mutations in the PI3K-AKT pathway are most
frequent in TAL1-positive T-ALL cases, while activating muta-
tions in JAK1, JAK3 or IL7R, leading to constitutive STAT5 phos-
phorylation, are most often found in immature and TLX/HOXA-
positive T-ALL (de Bock et al., 2018; Liu et al., 2017). In addition
to IL7R-JAK mutations, ABL1 activation, through the generation
of fusion genes with NUP214, EML1, or ETV6, results in aberrant
STAT5 activation (De Keersmaecker et al., 2008a). The NUP214-
ABL1 fusion is the most frequent ABL1 fusion in T-ALL, which is
generated by episomal amplification (Graux et al., 2004). The
NUP214-ABL1 kinase is able to confer cytokine-independent
growth to Ba/F3 cells and to drive T cell leukemia when overex-
pressed from viral vectors in mouse bone marrow cells in vivo
(De Keersmaecker et al., 2008a). Compared with BCR-ABL1,
NUP214-ABL1 is a relatively weak oncoprotein with lower kinase
activity, and a 2- to 3-fold higher sensitivity to the kinase inhib-
itor imatinib (De Keersmaecker et al., 2008b). Patients with
NUP214-ABL1-positive T-ALL have been treated with imatinib,
albeit with variable success (Clarke et al., 2011; Crombet et al.,
2012; Deenik et al., 2009; Koschmieder et al., 2014; Stergianou
et al., 2005).
From numerous sequencing studies, it has become evident
that NUP214-ABL1+ T-ALL cases are almost exclusively found
within TLX1/3-positive cases (Graux et al., 2009; Kleppe et al.,
2010; Liu et al., 2017). This association between NUP214-
ABL1 and TLX1/3 expression suggests a possible synergism be-
tween these two oncogenic aberrations in driving the develop-
ment, progression, and/or maintenance of T-ALL, which we
have investigated in the current study.
RESULTS
The NUP214-ABL1 Fusion and TLX1/TLX3 Expression
Co-occur in T-ALL Patients and Cooperate in the
Development of T-ALL in a Transgenic Mouse Model
The NUP214-ABL1 kinase is a known driver of proliferation in
T-ALL (Graux et al., 2004; Kleppe et al., 2010). Examination of
publicly available clinical T-ALL sequencing data (Burmeister
et al., 2006; Graux et al., 2004, 2009; Homminga et al., 2011;
Liu et al., 2017; Soulier et al., 2005) confirmed that within the
NUP214-ABL1+ cases, almost all cases are TLX1/TLX3 positive,
while in a general T-ALL cohort only 32% of the cases are TLX1/
TLX3 positive (p < 0.0001) (Figure 1A and Table S1). This signif-
icant co-occurrence between NUP214-ABL1 and TLX1/3 in
T-ALL patients suggested that these lesions might cooperate
in the initiation, development, and/or maintenance of T-ALL.
To investigate the potential cooperation of NUP214-ABL1 with
TLX1, we generated a conditional transgenic mouse model
Tg(NUP214-ABL1), in which the expression of NUP214-ABL1-
IRES-GFP is blocked by a LoxP stop cassette (hereafter desig-
nated LSL-NA, Figures 1B and S1A). These mice were subse-
quently crossed with Tg(CD4-Cre) mice for targeted expression
of NUP214-ABL1 within developing T cells beginning from
the CD4+CD8+ double-positive stage (hereafter designated
NA mice, Figures 1B and S1A). CD4-Cre-driven expression
of NUP214-ABL1 alone was insufficient to cause T-ALL
Co-expression of NUP214-ABL1 and TLX1 was achieved by crossing NA mice with Tg(Lck-TLX1) mice, resulting in Tg(CD4 Cre; NUP214-ABL1; Lck TLX1) mice
(abbreviated as NA + TLX1).
(C) Kaplan-Meier overall survival curve comparing NA + TLX1, TLX1, and NA mice.
(D) Representative fluorescence-activated cell sorting (FACS) analysis of GFP expression in NA + TLX1mice at end-stage disease compared with wild-type (WT)
cells for spleen, thymus, peripheral blood (PB), and bone marrow (BM).
(E–G) Peripheral white blood cell count (WBC) (E), spleen weight (F), and thymus weight (G) at end-stage disease for NA + TLX1mice compared with NA and LSL-
NAmice (end stage for NA and LSL-NA defined as >360 days). Star indicates NA + TLX1mouse that presented with an elevatedWBC, but did not present with an
enlarged spleen or thymus at end stage. Statistical significance was calculated using a Mann-Whitney test. Data are presented as mean ± SD. N.s., not
significant.
(H) Representative FACS analysis for CD4 and CD8 expression in GFP-positive NA + TLX1 leukemic cells from the peripheral blood compared with NA and
LSL-NA peripheral blood cells.
(I) H&E and immunohistochemical staining for CD3 and Cre in spleen cells from LSL-NA, NA, and NA + TLX1 mice. Scale bars represent 100 mm.
(J) Kaplan-Meier overall survival curve of secondary (using cells from three different primary NA + TLX1 mice) and tertiary transplants.
(K) Growth curve of ex vivo primary immature pro T cells expressing EML1-ABL1, TLX1 or both. Data are presented as mean ± SD.
(L) Kaplan-Meier overall survival curve of mice transplanted with hematopoietic stem/progenitor cells expressing EML1-ABL1, TLX1 or EML1-ABL1+TLX1.
See also Figures S1–S4 and Table S1.
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Figure 2. NUP214-ABL1 and TLX1 Upregulate the JAK-STAT Pathway
(A) Transcription factor binding motifs of the top transcription factors identified by i-CisTarget to regulate NA + TLX1 gene expression patterns. NES, normalized
enrichment score.
(B) i-CisTarget transcriptional network showing genes regulated by STAT5.
(C) Heatmap representing the differential gene expression of canonical JAK-STAT signaling pathway genes in WT, NA, TLX1, and NA + TLX1 mice.
(D) Gene set enrichment analysis (GSEA) showing enrichment of STAT5 target genes (as defined by ChIP-seq) in the differentially expressed genes in NA + TLX1
mice compared with WT. NES, normalized enrichment score.
(E) qRT-PCR analysis of Myc and Bcl2 mRNA in the different transgenic mouse models. Statistical significance calculated using unpaired two-tailed t test with
equal variance. Data are presented as mean ± SD.
(F) qRT-PCR analysis of Myc and Bcl2 in ex vivo immature pro T cells expressing EML1-ABL1, TLX1 or both. Statistical significance calculated using unpaired
two-tailed t test with equal variance. Data are presented as mean ± SD.
(G) qRT-PCR in ALL-SIL cells after a 2-day antisense oligo-mediated knockdown of STAT5A or STAT5B. Data are presented as mean ± SD.
(legend continued on next page)
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development in theNAmousemodel over a 400-day observation
period, and there were no profound T cell developmental defects
(Figures 1C and S1B–S1G). Similarly, crossing the LSL-NA mice
with CD2-Cre or CD19-Cre drivers, to activate NUP214-ABL1
expression in the common lymphoid progenitor or B cell pro-
genitor stages, did not result in strong lymphoid abnormalities
or disease development (Figure S2). Together, these data
show that the expression of a single copy of NUP214-ABL1
within lymphoid progenitors was insufficient to drive leukemia
development.
We next sought to determine whether co-expression of TLX1
with NUP214-ABL1 could drive T-ALL development. To this
end, NA mice were crossed with Tg(Lck-TLX1) mice (designated
TLX1) (Figure 1B), expressing TLX1 under control of the T cell-
specific Lck promoter (De Keersmaecker et al., 2010), and this
resulted in mice in which both NUP214-ABL1 and TLX1 were ex-
pressed in developing T cells (designated NA + TLX1) (Figures
1B, S3A, and S3B). In this instance, NA + TLX1 mice developed
an aggressive T cell leukemia with a significantly shorter latency
(median overall survival = 217 days) compared with TLX1 mice
(median overall survival = 385 days) and NA mice (no leukemia)
(p < 0.001). At end-stage disease, all NA + TLX1 mice had
leukemic cell infiltration into the spleen, thymus, and bone
marrow (Figure 1D), and the leukemic cells showed strong phos-
phorylation of STAT5, a downstream effector of NUP214-ABL1
(Figures S3C and S3D). Leukemic mice had increased white
blood cell counts, with the majority also presenting with spleno-
megaly and enlarged thymi (Figures 1E–1G). Phenotypic analysis
revealed that the major leukemic clone in the NA + TLX1 mice
was an immature CD4+CD8+ T cell population (Figure 1H). Histo-
pathological analysis further confirmed a T cell leukemia with se-
vere expansion of the white pulp and infiltration of the red pulp by
atypical CD3+ lymphoid cells, resulting in the loss of splenic tis-
sue architecture in NA + TLX1 mice (Figure 1I). The disease was
transplantable to secondary and tertiary transplants, confirming
the disease to be an acute leukemia (Figure 1J).
To further extend these findings, we tested whether TLX1
could cooperate with EML1-ABL1, another ABL1 fusion de-
tected in TLX1-positive T-ALL (Vanden Bempt et al., 2018; De
Keersmaecker et al., 2005). First, we tested co-expression of
EML1-ABL1 and TLX1 in ex vivo cultured primary mouse pro
T cells (Bornschein et al., 2018; Gehre et al., 2015). Cells ex-
pressing EML1-ABL1 and TLX1 proliferated in the absence of
interleukin-7 (IL-7) and outcompeted cells expressing EML1-
ABL1 or TLX1 alone (Figure 1K). Next, to confirm these findings
in vivo, we transplanted murine hematopoietic stem/progenitor
cells transduced with retroviral vectors containing EML1-ABL1,
TLX1, or EML1-ABL1 + TLX1 into irradiated recipient mice. After
100 days, 5 of 8 (63%) of the EML1-ABL1 + TLX1mice had devel-
oped a fatal leukemia, whereas EML1-ABL1 or TLX1 alone was
not able to induce leukemia during the observation period (Fig-
ures 1L and S4). Taken together, these data show that both
NUP214-ABL1 and EML1-ABL1 can cooperate with TLX1 to
transform T cells ex vivo and induce leukemia in vivo.
NUP214-ABL1/TLX1-Driven Leukemia Cells Are
Characterized by a STAT5 Gene Signature
To elucidate the underlying transcriptional programs and identify
key transcription factors driving the leukemia development in
NA + TLX1 mice, we performed a global gene expression anal-
ysis using RNA sequencing (RNA-seq) in conjunction with an in
silico analysis of regulatory sequences using i-CisTarget (Herr-
mann et al., 2012; Verfaillie et al., 2015). Genes that were most
significantly up- or downregulated in NA + TLX1 CD4+CD8+
leukemia cells compared with normal CD4+CD8+ T cells were
enriched for STAT5, SPI1, and ETS/RUNX binding sites in their
regulatory regions (Figures 2A and 2B). In addition, we found sig-
nificant upregulation of the JAK-STAT pathway genes in NA +
TLX1 leukemic cells (Figures 2C and S5A). STAT5 is indeed
known to be phosphorylated and activated by NUP214-
ABL1 (De Keersmaecker et al., 2008a). To specifically determine
the contribution of STAT5 target genes, we performed
ChIP sequencing (ChIP-seq) with anti-STAT5 antibodies. We
observed a strong enrichment of the genes bound by STAT5
(as defined by ChIP-seq) in the upregulated transcripts in the
NA + TLX1 leukemic cells compared with wild-type (WT)
CD4+CD8+ T cells (Figures 2D and S5B). Many of the upregu-
lated genes, including Myc and Bcl2, are known as canonical
STAT5 target genes (Figures 2E and S5C). In addition, activation
of STAT5 and expression of TLX1 together led to increased
expression ofMyc andBcl2 comparedwith STAT5 or TLX1 alone
in ex vivo cultured pro T cells (Figure 2F).
These data indicate that NA + TLX1 leukemia cells are largely
characterized by activation of STAT5 target genes. To further
determine the contribution of STAT5 and TLX1 in transcriptional
regulation, we knocked down STAT5A/STAT5B or TLX1 in the
human T-ALL cell line ALL-SIL (expressing NUP214-ABL1 and
TLX1), and found that STAT5 target genes were in both cases
downregulated (Figures 2G, 2H, S5D, and S5E). Moreover, inhi-
bition of STAT5 activation by treatment of the cells with the ABL1
kinase inhibitor imatinib led to downregulation of the STAT5
target genes (Figures 2I, 2J, and S5F–S5H), and these genes
significantly overlapped with the set of genes specific for the
mouse NA + TLX1 leukemia cells (p < 0.001) (Figure 2K). In
(H) GSEA to show enrichment of TLX1 target genes (genes with a TLX1 ChIP peak and downregulated after TLX1 gapmer treatment) in differentially expressed
genes after imatinib treatment. NES, normalized enrichment score.
(I–K) Volcano plot (I) showing up- and downregulated genes (top) and GSEA to show enrichment of STAT5 target genes in differentially expressed genes (bottom)
after imatinib treatment (500 nM imatinib or DMSO for 3 hr) in leukemic cells harvested from NA + TLX1 mice (n = 3; experiment was performed with cells
harvested from three separate mice). (J) Volcano plot showing up- and downregulated genes (top) and GSEA to show enrichment of STAT5 target genes in
differentially expressed genes (bottom) after imatinib treatment (500 nM imatinib or DMSO for 3 hr) in ALL-SIL cells (n = 3; experiment was performed as three
independent repeats). (K) Venn diagram showing overlap between the upregulated genes in NA + TLX1 versus WT mice and genes that are downregulated after
imatinib treatment (p = 8.7 3 10159).
(L) Cell number of NA + TLX1 spleen cells expressing STAT5 N642H or empty vector, treated for 48 hr with 500 nM imatinib or DMSO. Data are presented as
mean ± SD.
See also Figure S5.
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addition, expression of a constitutive active STAT5B(N642H)
mutant (Ariyoshi et al., 2000; Bandapalli et al., 2014) in mouse
NA + TLX1 leukemia cells could rescue the effect of imatinib
treatment on cell viability (Figure 2L), confirming that STAT5 is
one of the major factors driving the proliferation and survival of
the NA + TLX1 leukemia cells. Taken together, these gene
expression data indicate a strong STAT5 signature in the NA +
TLX1 leukemia cells, with marked upregulation of STAT5 target
genes in the presence of TLX1.
TLX1 and STAT5 Have Overlapping Binding Sites
Genome-wide and Are Preferentially Associated with
Enhancer Regions
To gain further insight into how the STAT5 and TLX1 transcription
factors might cooperate in the transcriptional regulation of NA +
TLX1-driven leukemia, we mapped the binding sites of STAT5
and TLX1 genome-wide. ChIP-seq analysis of murine NA +
TLX1 leukemic cells revealed that STAT5 and TLX1 binding sites
overlap significantly throughout the genome (p < 0.001) and that
binding was enriched in imatinib-responsive genes. Motif anal-
ysis showed that RUNX motifs were highly enriched in the
STAT5/TLX1 binding sites. Indeed, RUNX1 also co-binds with
STAT5 and TLX1 in the leukemic cells as confirmed by ChIP-
seq (Figures 3A and 3B). STAT5 and TLX1 predominantly co-
occupy enhancer regions, as shown by the presence of
enhancer marks p300, BRD4, and H3K27ac. These regions
were already bound by RUNX1 in normal CD4+CD8+ T cells,
where they were marked with H3K4me1 rather than H3K27ac,
indicating that these regions are in a poised state inWT cells (Fig-
ures 3A and 3C). Given the strong co-occupancy at enhancers,
we next ranked the H3K27ac signals from regions bound by
TLX1 to identify important regulatory regions, also referred to
as super-enhancers. Many TLX1-bound regions were found
to contain high-intensity H3K27ac signals (Figure 3D). These
enhancer regions included numerous STAT5 responsive genes
with strong H3K27ac signals localized either intragenically
(e.g., Bcl2) or downstream (e.g., Socs1 and Pim1) and were
marked by p300 and BRD4 enhancer marks, but not by the pro-
moter-associated H3K4me3 mark (Figures 3E–3G). These data
show that STAT5 and TLX1 cooperate on a genome-wide level
mainly by co-occupying regulatory enhancer regions.
TLX1Binding IsCorrelatedwithOpenEnhancerRegions
of STAT5 Response Genes
Given the strong correlation between STAT5 and TLX1 binding in
active enhancer regions, global chromatin architecture was
further investigated using assay for transposase-accessible
chromatin using sequencing (ATAC-seq). Comparing ATAC-
seq profiles of CD4+CD8+ NA + TLX1 leukemic cells with
CD4+CD8+ T cells from WT mice revealed that many STAT5
target genes had increased chromatin accessibility in NA +
TLX1 cells. An in silico analysis using i-CisTarget (Herrmann
et al., 2012; Verfaillie et al., 2015) identified STAT5, ETS1, and
RUNX1 binding motifs in the more accessible chromatin regions
(Figure 4A). These regions were found to be associated with
genes that are differentially expressed in NA + TLX1 mice (Fig-
ure 4B). Only 16% of all chromatin regions with appearing
ATAC peaks were located in promoter regions, while 42%
were located in enhancer regions (Figure 4C), indicating that
the gene expression changes in NA + TLX1 cells compared
with NA or TLX1 cells were mainly due to enhancer-mediated ef-
fects. Indeed, we found that the more accessible regions in the
NA + TLX1 leukemic cells were mostly marked by the H3K27ac
enhancer mark, and only rarely by the H3K4me3 promoter
mark (Figure 4D). A global comparison of ATAC peaks between
non-leukemic WT, NA, and TLX1 CD4+CD8+ cells and leukemic
NA + TLX1 cells showed that regions that were previously inac-
cessible were now accessible, bound by STAT5, TLX1, p300,
and BRD4, and marked by H3K27ac. These regions were not
accessible in WT, NA, or TLX1 cells, nor was any H3K27ac
detected. However, these regions were already marked by
H3K4me1, showing that these enhancers are already in a poised
state in normal CD4+CD8+ thymocytes (Figure 4D). Among these
more accessible chromatin regions were the internal Bcl2
enhancer, the Pim1 downstream enhancer, and the Notch-
dependent Myc enhancer (N-ME) (Herranz et al., 2014; Ya-
shiro-Ohtani et al., 2014), while the promoter regions of these
genes showed only minimal changes in chromatin structure
(Figures 4E and S6).
TLX1 and STAT5 Activate a Feedforward Loop Engaging
MYC in TLX1/STAT5 Complexes
To determine whether TLX1 and STAT5 co-bound regulatory re-
gions were enriched for additional transcription factor binding
sites, we integrated ChIP-seq and RNA-seq data from mouse
and human leukemia cells and performed an in silico analysis us-
ing i-CisTarget (Herrmann et al., 2012; Verfaillie et al., 2015). This
analysis revealed that MYC and MAX binding motifs were signif-
icantly enriched specifically in genes positively regulated by
STAT5 (i.e., downregulated after imatinib treatment) (Figure 5A).
To verify MYC binding to these regions, we performed ChIP-seq
experiments with MYC antibodies to characterize genome-wide
binding sites of MYC in human ALL-SIL cells. Strikingly, the bind-
ing pattern of MYC overlapped significantly with STAT5 and
Figure 3. STAT5 and TLX1 Co-bind Regulatory Regions throughout the Genome
(A) Centered read density heatmaps of ChIPmentation ChIP-seq signals for the binding of TLX1, STAT5, p300, BRD4, ETS1, RUNX1, and the histone marks
H3K27ac and H3K4me1. Heatmaps centered and ranked on TLX1 signal strength in leukemic NA + TLX1 and WT mouse cells.
(B) GSEA comparing genes bound by both STAT5 and TLX1 and differentially expressed genes after treatment with imatinib in ALL-SIL cells.
(C) Venn diagram showing the total amount of TLX1 and STAT5 peaks that fall within the 90,804 H3K27ac peaks for NA + TLX1 leukemic cells (left). Pie chart (right)
showing ChIP-seq peak co-occurrence of STAT5 and TLX1 in mouse NA + TLX1 leukemic cells in relation to promoter regions (H3K4me3+/H3K27ac+) and
enhancer regions (H3K27ac+/BRD4+/p300+/H3K4me3).
(D) Enhancer regions ranked on H3K27ac signal for NA + TLX1 leukemic cells and ALL-SIL. Only H3K27ac clusters with overlapping TLX1 peaks are shown. Gene
labels are distance-based if not intragenic.
(E–G) Representative ChIP-seq tracks for canonical STAT5 target genes Bcl2 (E), Pim1 (F), and Socs1 (G) showing STAT5, TLX1, H3K4me3, p300, BRD4, and
H3K27ac binding in NA + TLX1 leukemic mouse cells.
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Figure 4. TLX1 and STAT5 Bind in Newly Accessible Enhancer Regions
(A) Volcano plot of differential ATAC-seq peak height in CD4+CD8+ NA + TLX1 leukemic cells versus CD4+CD8+ WT cells. Peaks in STAT5 response genes are
shown as blue dots. Transcription factor binding motifs enriched through i-CisTarget analysis in the appearing peaks are shown on the right. NES, normalized
enrichment score.
(B) GSEA of appearing ATAC peaks in relation to differentially expressed genes in CD4+CD8+ NA + TLX1 leukemic cells versus CD4+CD8+ WT cells.
(C) Pie chart representing the genomic locations of appearing ATAC-seq peaks in CD4+CD8+ NA + TLX1 cells versus CD4+CD8+ WT cells. A promoter region is
defined as a region with combined H3K4me3 and H3K27ac marks. An enhancer region is defined as a region with H3K27ac signal or BRD4 binding or p300
binding, but no H3K4me3.
(D) Read density heatmaps of ATAC-seq and ChIP-seq signals (STAT5, TLX1, p300, BRD4, H3K27ac, H3K4me1, H3K4me3) in CD4+CD8+ WT, NA, TLX1, and
NA + TLX1 cells, centered around the top 2,000 appearing and disappearing ATAC-seq peaks.
(E) ATAC-seq tracks (performed in CD4+CD8+ WT, NA, TLX1, and NA + TLX1 cells) and ChIP-seq tracks (H3K4me1, H3K27ac in WT cells and STAT5, TLX1,
H3K27ac in NA + TLX1 cells) at the Bcl2 locus, the Pim1 locus, and the Myc locus.
See also Figure S6.
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TLX1 (p < 0.001) (Figures 5B and 5C).Moreover, MYCwas bound
together with STAT5 and TLX1 in regulatory regions of STAT5
target genes, e.g. OSM, PIM1, BCL2, and MYC (Figures 5D–
5G). To determine whether MYC was actively involved in the
regulation of these genes, we treated the cells with MYC small
interfering RNA (siRNA) or with the BET inhibitor JQ1, which indi-
rectly causes MYC downregulation. Knockdown of MYC led to a
reduction of STAT5 target gene expression, supporting an active
role for MYC in the expression of STAT5 target genes in the leu-
kemia cells expressing NUP214-ABL1 and TLX1 (Figures 5H and
5I). A more detailed analysis of the MYC locus revealed that
STAT5 and TLX1 were bound to the promoter region (Figure 5G)
as well as to regions within the 1.4-Mb downstream super-
enhancer region. This downstream super-enhancer region has
a well-characterized Notch-dependent enhancer region (N-ME)
(Herranz et al., 2014; Yashiro-Ohtani et al., 2014) and also previ-
ously characterized STAT5 binding regions (Pinz et al., 2016;
Shi et al., 2013). These regions were characterized by a strong
H3K27ac signal and distinct regions co-bound by BRD4,
STAT5, TLX1, and MYC itself (Figure 5J), suggesting a feedfor-
ward loop in the regulation of MYC expression.
Taken together, these data show that MYC upregulation in
NUP214-ABL1/TLX1 leukemic cells is a direct effect of STAT5
and TLX1 binding to regulatory regions, and that MYC reinforces
the transcriptional program initiated by these transcription
factors.
Downstream Effectors of NUP214-ABL1 and TLX1 Can
Be Targeted to Improve Treatment Strategies
Having established a role for STAT5, MYC, and TLX1 in the
expression of key regulatory genes controlling cell survival and
proliferation through enhancer activation, we sought to exploit
these findings using a targeted therapeutic approach within
NUP214-ABL1-positive patient T-ALL samples. Given that
NUP214-ABL1 and TLX1 activate enhancer regions, we tested
the therapeutic efficacy of BET inhibitors, which are known to
disrupt active enhancers (Love´n et al., 2013). In addition, we
selected to inhibit BCL2 as a downstream target of NUP214-
ABL1 and TLX1, since a small-molecule inhibitor is already avail-
able for this target (Souers et al., 2013).
Treatment of ALL-SIL cells or T-ALL patient-derived xenograft
(PDX) cells (X12 and XD82, Figures S7A and S7B) showed
reduced viability upon treatment with imatinib (ABL1 inhibitor),
JQ1 (BET inhibitor), and ABT-199 (BCL2 inhibitor, Venetoclax).
Treatment with a combination of these inhibitors was even
more potent (Figures 6A–6C). To explore the synergistic proper-
ties of the different inhibitors in more detail, we combined imati-
nib with a BET inhibitor (JQ1, iBET-762 or CPI0610) (Figures 6D,
6E, and S7C–S7H) or a BCL2-inhibitor (ABT-199) (Figures 6F,
6G, and S7I–S7L). We calculated synergy using the zero interac-
tion potential (ZIP) method, and observed a clear average syner-
gistic effect for all combinations. Moreover, we showed that the
maximum ZIP synergy score for each combination exceeds 10,
which means a 10% additional cell inhibition due to the synergy,
compared with a solely additive effect of the two drugs (Ianevski
et al., 2017). Combining imatinib with JQ1 resulted in a stronger
reduction of BCL2 expression compared with the single agents
(Figure 6H), which was in line with the more drastic inhibitory
effect of the inhibitor combination on cell viability.
To test the combination treatment in vivo, we injected NSG
mice with X12 PDX cells, and treated these mice for 10 consec-
utive days with imatinib, JQ1, ABT-199, or a combination of im-
atinib with JQ1 or ABT-199. Combined treatment with imatinib
and JQ1 or ABT-199 reduced leukemia burden significantly
more than single agents (Figures 6I–6L, S7M, and S7N). Investi-
gation of expression data from NUP214-ABL1+ T-ALL cases (Liu
et al., 2017) confirmed that MYC and BCL2 levels are consis-
tently high in these cases, providing evidence that this subgroup
could indeed benefit from combined treatment with imatinib and
BET or BCL2 inhibitors (Figure 6M).
In summary, we have shown that STAT5, MYC, and TLX1
cooperatively activate key target genes implicated in prolifera-
tion and survival. Inhibition of these downstream targets of
STAT5, MYC, and TLX1 together with inhibition of NUP214-
ABL1 greatly improves therapy response in relevant T-ALL pa-
tient samples and could be a viable treatment option for
NUP214-ABL1+ patients (Figure 7).
DISCUSSION
Recent next-generation sequencing studies encompassing
large cohorts of T-ALL patient samples have led to the identifica-
tion of a large number of mutations across multiple genes, indi-
cating that on average ten or more potential oncogenic lesions
are found in the leukemia cells at diagnosis (De Keersmaecker
et al., 2013; Liu et al., 2017; Seki et al., 2017; Vicente et al.,
2015). Based on these large datasets, we are now able to
observe specific and recurrent associations between genetic
Figure 5. MYC Co-binds and Co-regulates STAT5 and TLX1 Target Genes
(A) In silico i-CisTarget analysis for enriched transcription factor motifs found within in regulatory regions of genes that are positively or negatively regulated
by STAT5.
(B) Read density heatmaps of ChIP-seq signals on TLX1 binding locations for different transcription factors or epigenetic marks ranked on TLX1 signal strength
(top) or STAT5 signal strength (bottom) in ALL-SIL cells.
(C) Venn diagram showing the total amount of TLX1 and STAT5 peaks that fall within the 41,229 H3K27ac peaks (left) and the total amount of STAT5 + TLX1 peaks
that overlap with MYC peaks (right) in ALL-SIL cells.
(D–G) ChIP-seq tracks (performed on ALL-SIL cells) of STAT5, TLX1, MYC, p300, BRD4, and H3K27ac at canonical STAT5 regulated genes OSM (D), PIM1 (E),
BCL2 (F), and MYC (G) loci.
(H) qRT-PCR in ALL-SIL cells treated with MYC siRNAs for 48 hr. Data are presented as mean ± SD. Statistical significance calculated using unpaired two-tailed
t test with equal variance.
(I) qRT-PCR of STAT5 target genes in ALL-SIL cells treated with 500 nM JQ1 for 6 hr. Data are presented as mean ± SD. Statistical significance calculated using
unpaired two-tailed t test with equal variance.
(J) ChIP-seq tracks (performed on ALL-SIL cells) of STAT5, TLX1, MYC, p300, BRD4, and H3K27ac at the MYC enhancer locus, 1.4 Mb downstream of the
MYC gene.
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Figure 6. Downstream Effectors of NUP214-ABL1 and TLX1 Can Be Targeted to Improve Treatment Strategies
(A) Viability of ALL-SIL cells after 48 hr treatment with 500 nM imatinib, 500 nM JQ1, 500 nM ABT-199, or a combination of these inhibitors (500 nM + 500 nM).
(n = 3; experiment was performed as three independent repeats, and data are presented as mean ± SD).
(B) Viability of NUP214-ABL1+TLX3+ X12 PDX cells after 48 hr treatment with 500 nM imatinib, 500 nM JQ1, 500 nM ABT-199, or a combination of these inhibitors
(500 nM + 500 nM). Statistical significance calculated using unpaired two-tailed t test with equal variance (n = 2; the experiment was performed using cells
harvested from two different xenograft mice, and data are presented as mean ± SD). Statistical significance calculated using unpaired two-tailed t test with equal
variance.
(legend continued on next page)
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aberrations, implying a degree of reciprocal dependency and
potential cooperation. One of the challenges that remains is to
functionally assess whether these associations are indeed coop-
erative and whether they are essential oncogenic drivers of the
disease. Subsequent to this confirmation, it is important to deter-
mine whether these cooperatingmutations drive leukemia devel-
opment either by initiating separate but complementary changes
in the cell or by directly cooperating with each other at the
signaling or transcriptional level.
In this study, we reanalyzed genetic data from 457 T-ALL pa-
tients (Burmeister et al., 2006; Graux et al., 2004, 2009; Hom-
minga et al., 2011; Liu et al., 2017; Soulier et al., 2005) and
(C) Viability of NUP214-ABL1+TLX3+ XD82 PDX cells after 48 hr treatment with 500 nM imatinib, 500 nM JQ1, 500 nM ABT-199, or a combination of these in-
hibitors (500 nM + 500 nM) (n = 2; the experiment was performed using cells harvested from two different xenograft mice, and data are presented as mean ± SD).
Statistical significance calculated using unpaired two-tailed t test with equal variance.
(D) Growth of X12 PDX cells after 48 hr treatment with imatinib with or without JQ1 (1 mM). Data are presented as mean ± SD.
(E) Synergy matrix plot showing d-scores for X12 PDX cells treated with imatinib + JQ1 (average ZIP synergy score = the average d-score for the whole range of
concentrations shown in the synergy matrix; max ZIP synergy score = maximal score for a specific dose combination).
(F) Growth of X12 PDX cells after 48 hr treatment with imatinib with or without ABT-199 (0.5 mM). Data are presented as mean ± SD.
(G) Synergymatrix plot showing d-scores for X12 PDX cells treated with imatinib + ABT-199 (average ZIP synergy score = the average d-score for the whole range
of concentrations shown in the synergy matrix; max ZIP synergy score = maximal score for a specific dose combination).
(H) qRT-PCR analysis of BCL2 and MYC mRNA expression levels in ALL-SIL cells after 6 hr of treatment with 500 nM imatinib, 500 nM JQ1, or in combination.
Data are presented as mean ± SD. Statistical significance calculated using unpaired two-tailed t test with equal variance.
(I and J) Percentage of human CD45 cells detected by flow cytometry in peripheral blood samples (I) or spleen samples (J) of mice treated for 10 days with JQ1
(50 mg/kg/day), imatinib (100 mg/kg/day), or a combination of imatinib + JQ1. Data are presented as mean ± SD.
(K) Spleen weight of mice treated with JQ1, imatinib, or a combination of imatinib + JQ1. Data are presented as mean ± SD.
(L) Percentage of humanCD45 detected by flow cytometry in peripheral blood samples ofmice treatedwith ABT-199 (20mg/kg/day), imatinib (100mg/kg/day), or
a combination of imatinib + ABT-199. Gray bar indicates treatment period. imatinib versus imatinib + ABT-199: p = 0.0048 (unpaired t test). ABT-199 versus
imatinib + ABT-199: p = 0.0027 (unpaired t test). Data are presented as mean ± SD.
(M) Expression levels ofMYC (left), BCL2 (middle), and PIM1 (right) in patients from different T-ALL subgroups. Patients harboring the NUP214-ABL1 fusion are
represented by an orange star. Statistical significance was calculated using a Mann-Whitney test. Data are presented as mean ± SD.
See also Figure S7.
Figure 7. Schematic Overview of the Mech-
anism of Cooperation between STAT5
and TLX1
confirmed that the NUP214-ABL1-posi-
tive subgroup of T-ALL is significantly
and almost exclusively associated with
ectopic TLX1 or TLX3 expression, sug-
gesting potential cooperation between
NUP214-ABL1 signaling and TLX-driven
transcriptional deregulation. Previous
studies have shown that NUP214-ABL1
or TLX1 expression alone can lead to the
development of T-ALL in mouse models,
albeit with a long latency. Using a trans-
genic mouse model, we show that
NUP214-ABL1 and TLX1 co-expression
indeed accelerates T-ALL development.
Both genetic and functional data
described here demonstrate that STAT5
is a key player in the cooperation of
NUP214-ABL1 with TLX1/TLX3. STAT5
is phosphorylated and activated by
NUP214-ABL1, and we show that, in the
leukemic context, STAT5 and TLX1 co-
bind regulatory regions genome-wide
and regulate target gene expression mainly through the activa-
tion of otherwise silent/poised and inaccessible enhancers.
Our finding that STAT5 and TLX1 regulate the expression of
their target genes mainly through binding of more accessible
enhancer regions indicates that leukemia development in this
model is mainly driven by cell-identity-specific genes (Hnisz
et al., 2013; Zeng et al., 2016). TLX1- and STAT5-occupied re-
gions were bound by typical enhancer marks BRD4 and p300,
both of which are necessary for transcriptional elongation, and
were also marked by H3K27 acetylation.
MYC is a key oncogenic driver known as a general transcrip-
tional activator with a large number of target genes, affecting
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many different cellular processes, including cell growth and
genomic instability (Adhikary and Eilers, 2005). We document
co-binding of STAT5 and TLX1 at the Notch-dependent MYC
enhancer (N-ME) 1.4Mb downstream of theMYC promoter (Her-
ranz et al., 2014; Yashiro-Ohtani et al., 2014). No STAT5-TLX1
bindingwas detected at the blood enhancer cluster, an enhancer
region 1.7 Mb downstream of the MYC promoter important for
expression in B cells and granulocytes (Bahr et al., 2018; Shi
et al., 2013). Notably, in the current study MYC was found to
co-bind enhancer regions with STAT5 and TLX1 across the
genome, including the N-ME. Binding of MYC occurred specif-
ically to genes that were also sensitive to imatinib treatment,
and depletion of MYC resulted in downregulation of these imati-
nib-sensitive genes. Taken together, these findings indicate a
critical MYC-driven feedforward loop in the upregulation of
STAT5/TLX1 target genes implicated in leukemia development.
This mechanism of enhancer activation, combined with previ-
ously studied effects of TLX1 on NOTCH1 signaling and TCR
recombination (Dadi et al., 2012; Durinck et al., 2015; Della Gatta
et al., 2012; De Keersmaecker et al., 2010), can begin to explain
how NUP214-ABL1 and TLX1 drive the development of T-ALL.
Our findings on the cooperation of NUP214-ABL1 (through
STAT5) with TLX1 and MYC also provide opportunities for
improved treatment of NUP214-ABL1-positive T-ALL cases. Im-
atinib treatment to inhibit NUP214-ABL1 kinase activity and
STAT5 activation has been tested in several T-ALL patients,
with variable success (Clarke et al., 2011; Crombet et al., 2012;
Deenik et al., 2009; Koschmieder et al., 2014; Stergianou et al.,
2005). Now that we understand that STAT5 and TLX1 occupy
enhancer regions and that MYC is an important component of
the STAT5/TLX1 complex, inhibition of enhancer activity and/or
MYC expression may provide improved therapeutic opportu-
nities for these cases. Treatment of the NUP214-ABL1/TLX1-
expressing cell line ALL-SIL and human NUP214-ABL1/TLX3-
expressing T-ALL xenografts with the BET inhibitor JQ1 in
combination with imatinib showed synergistic anti-leukemia ef-
fects. Thus, this combination may be a viable treatment option
for NUP214-ABL1-positive T-ALL patients. The use of BET inhib-
itors could serve a double purpose in these cases by disrupting
activated enhancers in general and more specifically MYC
expression, since MYC expression depends strongly on the ac-
tivity of the downstream super-enhancer (Love´n et al., 2013).
Clinical trials are currently ongoing for multiple BET inhibitors
(Amorim et al., 2016; Berthon et al., 2016; Whitfield et al.,
2017). Additionally, combining imatinib with the BCL2-inhibitor
ABT-199 could also enhance therapy response.
In conclusion, we demonstrate that the oncogenic kinase
NUP214-ABL1, through its downstream effector STAT5, directly
cooperates with TLX1 at the transcriptional level. STAT5 and
TLX1 selectively increase the accessibility of enhancer regions
and drive a feedforward loop at theMYC enhancer, thereby rein-
forcing the activation of their oncogenic targets. Our data identify
MYC and BCL2 as novel targets for therapy in NUP214-ABL1-
positive T-ALL.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-CD45 (clone 2D1) (APC) Thermo Fischer Scientific Cat# 17-9459-42, RRID:AB_10718532
Rat monoclonal anti-CD4 (PE vio770) Miltenyi Biotec Cat# 130-102-784 RRID:AB_2659911
Rat monoclonal anti-CD8a (Vioblue) Miltenyi Biotec Cat# 130-102-431 RRID:AB_2659889
Rat monoclonal Anti-Gr1 (Vioblue) Miltenyi Biotec Cat# 130-102-233, RRID:AB_2659865
Rat monoclonal Anti-Cd11b (APC-vio770) Miltenyi Biotec Cat# 130-096-834, RRID:AB_2660135
Rat monoclonal anti-CD4 (clone GK1.5) (PE Cy7) Thermo Fischer Scientific Cat# 25-0041-81, RRID:AB_469575
Rat monoclonal anti-CD8a (clone 53-6.7) (APC Cy7) Thermo Fisher Scientific Cat# 47-0081-82, RRID:AB_1272185
Armenian hamster monoclonal anti-TCR-b
(clone H57-597) (PE)
Thermo Fischer Scientific Cat# 12-5961-82 RRID:AB_466066
Mouse monoclonal anti-phospho-Stat5 (pY694)
(PerCPCy5.5)
BD Biosciences Cat# 560118, RRID:AB_1645551
Rabbit monoclonal anti-Phospho-Stat5
(Tyr694) (C11C5)
Cell Signaling Technology Cat# 9359S, RRID:AB_823649
Rabbit polyclonal anti-Stat5 Cell Signaling Technology Cat# 9363, RRID:AB_2196923
Mouse monoclonal Anti-b–Actin (Clone AC-15) Merck Cat# A5441, RRID:AB_476744
Rabbit polyclonal anti-Stat5 (C17) Santa Cruz Biotechnology Cat# sc-835 RRID:AB_632446
Mouse monoclonal anti-Stat5 (A-9) Santa Cruz Biotechnology Cat# sc-74442 RRID:AB_1129711
Rabbit monoclonal anti-Stat5 (L-20) Santa Cruz Biotechnology Cat# sc-1081 RRID:AB_632448
Rabbit polyclonal anti-HOX11 (C18) Santa Cruz Biotechnology Cat# sc-880 RRID:AB_2203789
Rabbit polyclonal anti-MYC Santa Cruz Biotechnology Cat# sc-764 RRID:AB_631276
Rabbit anti-EP300 Santa Cruz Biotechnology Cat# SC-585X RRID:AB_2616339
Rabbit polyclonal anti-BRD4 Bethyl Cat# A301-985A50 RRID:AB_2631449
Mouse monoclonal anti-ETS1 (8A8) Thermo Fischer Scientific Cat# MA5-15609, RRID:AB_10978854
Rabbit polyclonal anti-RUNX1 Active Motif Cat# 39000
Rabbit anti-H3K4me1 Active motif Cat# 39297, RRID:AB_2615075
Rabbit monoclonal anti-H3K4me3 (clone C42D8) Cell Signaling Technology Cat# 9751, RRID:AB_2616028
Rabbit polyclonal anti-H3K27ac Abcam Cat# ab4729 RRID:AB_2118291
Rabbit polyclonal Anti-H3K27me3 Millipore Cat# 07-449, RRID:AB_310624
Rabbit monoclonal anti- Cre Recombinase
(D7L7L) XP
Cell Signaling Technology Cat# 15036
Goat polyclonal anti-CD3 epsilon Santa Cruz Biotechnology Cat# Sc-1127; RRID:AB_631128
Biological Samples
Patient-derived xenografts (PDX) This paper
Chemicals, Peptides, and Recombinant Proteins
Imatinib (Gleevec) Selleck Chemicals Cat# S2475; CAS ID:152459-95-5
JQ1 Selleck Chemicals Cat# S7110; CID ID: 1268524-71-5
ABT-199 MedChem Express Cat# HY-15531; CAS ID: 1257044-40-8
iBET-762 Merck Cat# SML1272; CAS ID: 1260907-17-2
CPI0610 Axon Med Chem Cat# 2594; CAS ID: 1380087-89-7
DMSO Millipore Cat# 102950; CAS ID: 67-68-5
Polybrene Infection / Transfection Reagent Merck Cat# TR-1003-G
Recombinant murine IL7 Peprotech Cat# 217-17
Recombinant murine IL6 Peprotech Cat# 216-16
Recombinant murine IL3 Peprotech Cat# 213-13
Recombinant murine SCF Peprotech Cat# 250-03
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
DLL4-Fc Bornschein et al., 2018
Mouse monoclonal anti-Human IgG1 Fc Abcam Cat# ab1927; RRID:AB_956021
1M Tris-HCI, pH 8.0 Thermo Fischer Scientific Cat# 15568025
Sodium dodecyl sulphate VWR Chemicals Cat# 444464T; Cas ID 151-21-3
Sodium deoxycholate Merck Cat# D6750; Cas ID: 302-95-4
Glycerol Thermo Fischer Scientific Cat# 15514-011
IGEPAL CA-630 Merck Cat# I8896; CAS ID: 9016-45-9
Triton X-100 Merck Cat# T8787 CAS ID: 9002-93-1
Tween 20 MP Biomedicals Cat# 11TWEEN201, CAS ID: 9005-64-5
Tween 40 Merck Cat# P1504; CAS ID: 9005-66-7
EDTA Millipore Cat# 108421; CAS ID: 6381-92-6
EGTA Merck Cat# E3889; CAS ID 67-42-5
NaCl Fischer Scientific Cat# S/3160; CAS ID: 7647-14-5
MgCl2 Merck Cat# M8266; CAS ID: 7786-30-3
LiCl Merck Cat# L4408; CAS ID: 7447-41-8
N-Lauroylsarcosine sodium salt solution 20% Merck Cat# L7414; CAS ID: 137-16-6
Formaldehyde Merck Cat# 25,254-9; CAS ID: 50-00-0
cOmplete Protease Inhibitor Cocktail, EDTA-free Merck Cat# COEDTAF-RO
Magna ChIP Protein A+G Magnetic Beads Millipore Cat# 16-663
Glycine Solution (10X) Cell Signalling Technology Cat# 7005S
ChIP Elution Buffer (2X) Cell Signalling Technology Cat# 7009S
5 M NaCl Cell Signalling Technology Cat# 7010S
Proteinase K Thermo Fischer Scientific Cat# EO0491
RNAse A Thermo Fischer Scientific Cat# EN0531
Tagmentation enzyme Illumina Cat# 15027916
Tagment buffer Illumina
KAPA HiFi HotStart Ready Mix KAPA Biosystems Cat# KK2602
Agencourt AMPure XP beads Fischer Scientific Cat# A63881
Resuspension buffer Illumina Cat# 15026770
Ethanol absolute VWR Cat# 20821.296, CAS ID: 64-17-5
Cell lysis buffer 10x Cell signaling technology Cat# 9803
Sodium Orthovanadate Merck Cat# 450243, CAS ID: 13721-39-6
cOmplete Protease Inhibitor Cocktail Merck Cat# CO-RO
Digitonin Merck Cat# D141; CAS ID: 11024-24-1
Formalin, 10% Sigma-aldrich Cat# F5554
Critical Commercial Assays
GoScript Reverse Transcriptase kit Promega Cat# A5001
Maxwell 16 LEV simplyRNA Purification Kit Promega Cat# AS1270
GoTaq qPCR Master Mix Promega Cat# A6001
MinElute PCR purification kit Qiagen Cat# 28006
ATPlite luminescence system Perkin Elmer Cat# 6016949
Easysep Mouse hematopoietic progenitor cell
isolation kit
Stem Cell Technologies Cat# 19856
Western lighting chemiluminescence reagent plus Perkin Elmer Cat# NEL105
ImmPRESS HRP Anti-Goat IgG (Peroxidase)
Polymer Detection Kit, made in Horse
Maravai Life Sciences Cat# MP-7405
EnVision+ System Agilent Cat# K400011-2
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Deposited Data
Raw and analyzed data This paper GSE102209
Human reference genome GRCh37/hg19 Genome Reference Consortium https://www.ncbi.nlm.nih.gov/grc/human
Mouse reference genome GRCm38/mm10 Genome Reference Consortium https://www.ncbi.nlm.nih.gov/grc/mouse
Experimental Models: Cell Lines
ALL-SIL DSMZ Cat# ACC-511, RRID:CVCL_1805
PEER DSMZ Cat# ACC 6, RRID:CVCL_1913
Experimental Models: Organisms/Strains
Mouse: C57BL/6 The Jackson lab Cat# 000664
Mouse: C57BL/6 LSL-NA GenOway N/A
Mouse: C57BL/6 NA This paper N/A
Mouse: C57BL/6 NA+TLX1 This paper N/A
Mouse: C57BL/6 TLX1 De Keersmaecker et al., 2010
Mouse: C57/BL/6 CD4-Cre The Jackson lab Cat# 017336
Mouse: C57/BL/6 CD2-Cre Vacchio et al., 2014,
The Jackson lab
Cat# 027406
Mouse: C57/BL/6 CD19-Cre The Jackson lab Cat# 018958
Oligonucleotides
Primers for genotyping This paper See Table S2
Primers for qRT-PCR This paper See Table S3
Negative control antisense LNA gapmer Qiagen Cat# LG00000002
TLX1 antisense LNA gapmer Qiagen Cat# 339511
STAT5A antisense LNA gapmer Qiagen Cat# 339511
STAT5A antisense LNA gapmer Qiagen Cat# 339511
STAT5B antisense LNA gapmer Qiagen Cat# 339511
STAT5B antisense LNA gapmer Qiagen Cat# 339511
Silencer Select Negative Control No. 1 siRNA Thermo Fischer Scientific Cat# 4390843
Silencer Select s9129 MYC siRNA Thermo Fischer Scientific Cat# 4392420
MYC siRNA sc-29226 Santa Cruz Biotechnology Cat# sc-29226
Recombinant DNA
MSCV-EML1-ABL1-IRES-GFP De Keersmaecker et al., 2005
MSCV-STAT5 N642H-IRES-GFP Bandapalli et al., 2014
MSCV-TLX1-IRES-mCherry This paper
Software and Algorithms
FlowJo FlowJo, LLC www.flowjo.com
GraphPad Prism Graphpad software www.graphpad.com
qBase+ Biogazelle www.qbaseplus.com
CLC Main workbench Qiagen Bioinformatics www.qiagenbioinformatics.com/products/
clc-main-workbench/
Integrative Genomics Viewer (IGV) Broad Institute software.broadinstitute.org/software/igv/
Bowtie2 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/
bowtie2/index.shtml
SAMtools Li et al., 2009 http://samtools.sourceforge.net/
MACS2 Zhang et al., 2008 https://github.com/taoliu/MACS
deeptools Ramı´rez et al., 2016 http://deeptools.readthedocs.io/en/latest/
RSAT peak-motifs Thomas-Chollier et al., 2012 http://pedagogix-tagc.univ-mrs.fr/rsat/
RSAT_portal.html
fastq-mcf Ea-utils https://github.com/ExpressionAnalysis/
ea-utils/blob/wiki/FastqMcf.md
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the Lead Contact, Jan Cools
(jan.cools@kuleuven.vib.be).
Tg(Lck TLX1) mice were provided by the lab of Adolfo Ferrando, af2196@columbia.edu.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
In Vivo Animal Studies
NSGmicewere bred in-house. Tg(Lck TLX1), Tg(CD4-Cre), Tg(CD2-Cre) and Tg(CD19-Cre) mice have been described elsewhere (De
Keersmaecker et al., 2010; Lee et al., 2001; Rickert et al., 1997; Sawada et al., 1994; Vacchio et al., 2014). Tg(NUP214-ABL1) mice
were developed in collaboration with genOway, France. A LoxP-Stop-LoxP NUP214-ABL1 IRES GFP expression cassette was
inserted into the Rosa26 locus via homologous recombination in embryonic stem cells, which were injected into blastocysts (Fig-
ure S1A). Crossing the offspring with wild-type females resulted in the creation of a Tg(NUP214-ABL1) mice strain. Tg(NUP214-
ABL1) mice were crossed with Tg(CD4 Cre) mice to generate the Tg (CD4 Cre;NUP214-ABL1) mouse model. Tg (CD4
Cre;NUP214-ABL1) mice were crossed with Tg(Lck TLX1) mice to generate the Tg(CD4 Cre;NUP214-ABL1;Lck TLX1) mouse model.
Primers for genotyping are listed in Table S2. Leukemia development was monitored by biweekly peripheral blood withdrawal. Sec-
ondary and tertiary transplants were performed using 6-8 weeks old in-house bred BL/6 recipient mice. For bone marrow transplant
assays, hematopoietic stem/progenitor cells were harvested from in-house bred BL/6mice using the EasySepMouseHematopoietic
Progenitor Cell Isolation Kit (Stem Cell Technologies). The cells were transduced with retrovirus for expression of the desired onco-
genes, and subsequently injected through tail-vein injection into recipient BL/6 mice. The survival of the mice was recorded daily. All
mice were kept in SPF or semi-SPF conditions in the KU Leuven animal facility. For ex vivo assays, cells were cultured in RPMI 1640
medium supplemented with 20% calf serum in 5% carbon dioxide at 37C. Mouse experiments were approved and supervised by
the KU Leuven ethical committee and conducted according to EU legislation (Directive 2010/63/EU).
Patient-Derived Xenograft (PDX) Samples
PDX sample X12 was a kind gift from prof. Jules Meijerinck (Princess Ma´xima Center for Pediatric Oncology, Utrecht). PDX sample
XD82 was a kind gift of prof. Jean-Pierre Bourquin (Department of Oncology and Children’s Research Center, University Children’s
Hospital Zurich, Zurich). Informed consent was obtained from all subjects. Patient PDX characteristics are shown in Figure S7. PDX
samples X12 and XD82were injected in NSGmice through tail vein injection: 1-3.106 cells (resuspended in 300 mL PBS) were injected
permouse. Expansion of the human leukemic cells wasmonitored by biweekly peripheral bloodwithdrawal and stained using human
CD45 staining (BD Biosciences, 560363). Cells were analysed usingMACSQuant Vyb (Miltenyi biotech). All data analysis was carried
out using FlowJo software (Treestar). Moribund mice were sacrificed and human leukemic cells were harvested from the spleen. For
ex vivo assays, cells were cultured in RPMI 1640medium supplementedwith 20%calf serum in 5%carbon dioxide at 37C. For in vivo
treatment studies, mice were injected with 2.106 X12 patient cells. When engraftment was established, mice were randomized
into the different treatment groups (4-5 mice per group) according to the percentage human CD45 detected in peripheral blood.
Mice were treated for 10 consecutive days. Imatinib was orally delivered (100 mg/kg/day). JQ1 (50 mg/kg/day) and ABT-199
(20 mg/kg/day) were delivered through intraperitoneal injection. Experiments on human samples were approved and supervised
by the UZ Leuven ethical committee.
Ex Vivo Primary T Cells
Ex vivo primary T cells (pro T cells) were generated from freshly harvested mouse (BL/6) hematopoietic stem/progenitor cells as pre-
viously described (Bornschein et al., 2018; Gehre et al., 2015). The pro T cells were transduced with retrovirus to express EML1-
ABL1-IRES-GFP, TLX1-IRES-mCherry or a combination of both. Then, the cells were grown for 4 days in the presence of immobilized
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
FastQC Babraham Bioinformatics https://www.bioinformatics.
babraham.ac.uk/projects/fastqc/
Tophat2 Kim et al., 2013 https://ccb.jhu.edu/software/tophat/
index.shtml
HTSeq Anders et al., 2015 http://htseq.readthedocs.io/en/
release_0.9.1/
DESeq2 Love et al., 2014 http://bioconductor.org/packages/
release/bioc/html/DESeq2.html
SynergyFinder Ianevski et al., 2017 https://synergyfinder.fimm.fi
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DLL4, but without interleukin 7 (IL7) or stem cell factor (SCF). Cell number, viability andGFP/mCherry percentage wasmeasured daily
on a MACSQuant Vyb (Miltenyi).
Cell Lines
ALL-SIL cells (source: male) and PEER cells (source: female) were obtained from DSMZ. The cells were cultured in RPMI 1640 me-
dium supplemented with 20% fetal calf serum (Invitrogen, CA, USA) in 5% carbon dioxide at 37C.
METHOD DETAILS
Flow Cytometry Analyses
Single-cell suspensions were prepared from spleen, thymus, bone marrow and lymph nodes. Peripheral blood was incubated in red
blood cell lysis buffer (150 mMNH4Cl, 0.1 mM EDTA, 10 mM KHCO3) for 5-10 minutes prior to staining. Cells were then washed with
PBS and stained for 20 minutes at 4C. Stained cells were washed with PBS and then analysed on either a FACSCanto flow cytom-
eter (BD Biosciences), a FACSverse flow cytometer (BD biosciences) or a MACSQuant Vyb (Miltenyi). Data was analysed with the
FlowJo software (Tree Star). Antibodies are listed in the Key Resources Table.
Virus Production and Viral Transduction
Viral particles were produced by HEK293T cells transfected (using GeneJuice transfection reagent (Millipore)) with an ecopac pack-
aging plasmid and the retroviral MSCV-EML1-ABL1-IRES-GFP, MSCV-STAT5 N642H-IRES-GFP or MSCV-TLX1-IRES-mCherry
expression plasmids. The supernatant carrying the viral particles was harvested after 48 hr.
1.106 primary T cells were seeded in 2 mL RPMI 1640 supplemented with 20% fetal calf serum (Invitrogen), IL7 (20 ng/mL), SCF
(20 ng/mL) and polybrene (8 mg/mL). 1 mL viral supernatant was added, and the cells were spinfected at 2500 rpm for 99 minutes at
30C. 4 hours after spinfection, the cells were transferred to a mDLL4-coated plate, and the medium was changed into RPMI 1640
supplemented with 20% fetal calf serum (Invitrogen), IL7 (20 ng/mL) and SCF (20 ng/mL), to remove polybrene and remaining viral
particles.
1.106 Hematopoietic stem/progenitor cells were seeded in 2 mL RPMI 1640 supplemented with 20% fetal calf serum (Invitrogen),
IL3 (10 ng/mL), IL6 (10 ng/mL), SCF (50 ng/mL) and polybrene (8 mg/mL). 1 mL viral supernatant was added, and the cells were spin-
fected at 2500 rpm for 99 minutes at 30C. 4 hours after spinfection, the medium was changed into RPMI 1640 supplemented with
20% fetal calf serum (Invitrogen), IL3 (10 ng/mL), IL6 (10 ng/mL) and SCF (50 ng/mL), to remove polybrene and remaining viral
particles.
1.106 NA+TLX1 spleen cells were seeded in 2 mL RPMI 1640 supplemented with 20% fetal calf serum (Invitrogen) and polybrene
(8 mg/mL). 1 mL STAT5 N642H-IRES-GFP viral supernatant was added, and the cells were spinfected at 2500 rpm for 99 minutes at
30C. 4 hours after spinfection, the medium was changed into RPMI 1640 supplemented with 20% fetal calf serum (Invitrogen), to
remove polybrene and remaining viral particles.
RNA Extraction, qRT-PCR and RNA-seq
RNA was extracted from tissue and cells using the Maxwell 16 LEV Simply RNA purification kit (Promega) according to the instruc-
tions of the manufacturer. RNA quality was measured using the 2100 BioAnalyzer (Agilent). cDNA synthesis was carried out using
GoScript (Promega) and qRT-PCR was performed using the GoTaq qRT-PCR master mix (Promega) with the ViiA7 Real Time
PCR system (Applied Biosystem). Primers used for qRT-PCR are listed in Table S3.
Libraries were sequenced on a HiSeq 2500 with 125bp single-end reads (Illumina). This RNA-sequencing data was first cleaned
(i.e. removal of adapters and low quality reads) with fastq-MCF (ea-utils) and a quality control was perfomed with fastQC. The reads
were then aligned with TopHat2 (Kim et al., 2013; Li et al., 2009) to the respective genomes, either Homo Sapiens (GRCh37/hg19) or
MusMusculus (mm10). To identify the gene expression HTSeq-count (Anders et al., 2015) was used to count the number of reads per
gene. These read count numbers were then normalized to the sample size. Differential gene expression analysis was performed with
the R-package DESeq2 (Love et al., 2014).
ChIPmentation ChIP-seq
ChIPmentation ChIP-seq was performed as described with minor modifications (Rendeiro et al., 2016; Schmidl et al., 2015). 20-40
million cells were washed in PBS and cross-linked with 1% formaldehyde for 10 min at room temperature and then quenched by
addition of glycine (125 mM final concentration). For Nuclei isolation, cells were resuspended in 1X RSB buffer (10 mM Tris
pH7.4, 10 mM NaCl, 3 mM MgCl2) and left on ice for 10 min to swell. Cells were collected by centrifugation and resuspended in
RSBG40 buffer (10 mM Tris pH7.4, 10 mM NaCl, 3 mM MgCl2, 10% glycerol, 0.5% NP40) with 1/10 v/v of 10% detergent (3.3%
w/v sodium deoxycholate, 6.6% v/v Tween-40). Nuclei were collected by centrifugation and resuspended in L3B+ buffer (10 mM
Tris-Cl pH 8.0, 100mMNaCl, 1 mMEDTA, 0.5 mMEGTA, 0.1%Na-Deoxycholate, 0.5%N-Lauroylsarcosine, 0.2%SDS). Chromatin
was fragmented to 200-400 bp using 20-25 cycles (30 s on, 30 s off, High) using the Bioruptor (Diagenode). The chromatin was sup-
plemented with 1% Triton-X100 after fragmentation. Antibodies (listed in the Key Resources Table) were preconjugated to either
magnetic protein A/G beads (Millipore) or magnetic protein-G beads (Celll Signaling Technology). Chromatin immunoprecipitation
was carried out overnight. Tagmentation and library preparation was performed using the Nextera DNA library prep kit (Illumina).
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DNA was purified using triple sided SPRI bead clean-up (1.2X, 0.6X, 0.9X). (Agencourt AMPure Beads, Beckman Coulter).
Sequencing was carried out by Illumina Hiseq 2000 (Illumina, San Diego, CA, USA). The raw ChIPmentation sequencing data was
first cleaned with fastq-MCF (ea-utils) after which a quality control was performed with fastQC. Subsequently it was mapped to
the human genome (GRCh37/hg19) or to the mouse genome (mm10) with Bowtie2 (Langmead and Salzberg, 2012). The peaks
were called with the MACS2 software (Zhang et al., 2008) using the input signal as background. For visualization purposes the
ChIP-signals were normalized with deeptools (Ramı´rez et al., 2014). To discover which motifs are enriched in the ChIP peaks the on-
line tool RSAT peak-motifs was used (Thomas-Chollier et al., 2012).
Fast-ATAC-seq
Fast-ATAC-seq was carried out as described with minor modifications (Corces et al., 2016), Briefly, 100,000 cells were resuspended
in transposase mix containing the tagmentation enzyme and 0,1% digitonin. Cells were incubated for 30 min at 37C. Tagmented
DNA was purified using MinElute columns (Qiagen). Library preparation was performed using the Nextera DNA library prep kit, Illu-
mina. DNA was purified using triple-sided SPRI bead clean-up. (Agencourt AMPure Beads, Beckman Coulter) using the following
ratio: 1.2X, 0.55X, 1.5X. Sequencing was carried out by Illumina Hiseq 2000 (Illumina, San Diego, CA, USA). The ATAC-sequencing
reads were processed similarly as the ChIPmentation data. The peak calling with MACS2 was performed without any background
signal. To identify differential peaks, all peak files were merged together with the bedtools software and transformed to a GFF file
which could then be used by HTSeq-count to count the number of reads per peak. A differential peak analysis was then performed
with the R package DESeq2.
Gene Set Enrichment Analysis
A ranked gene set enrichment analysis was performed with the BROAD GSEA software. For the RNA sequencing data a ranked
gene list was constructed from the differential gene expression results, in which the ranking value was calculated as –sign(log2FC)*
log(padj). Different gene sets were used, such as the KEGG pathway database, and custom gene sets like the genes with an appear-
ing ATAC-peak, or genes with certain ChIP-signals.
Western Blotting
Cell lysates were prepared using 1XCell Lysis Buffer (Cell Signaling) containing protease inhibitor (Complete – EDTA-free, Roche) and
1 mM Na3VO4. Proteins were separated by SDS-PAGE (NuPAGE 3-8% Tris-Acetate or NuPAGE 4-12% Bis Tris, Invitrogen) and
transferred to a nitrocellulose membrane using an iBlot Gel Transfer device (Thermo Fischer). Subsequent labelling was carried
out using unlabelled primary antibodies. Western blot detection was performed with secondary antibodies conjugated with horse-
radish peroxidase (GE Healthcare). Images were acquired using a cooled charge-coupled device camera system (ImageQuant
LAS-4000, GE Health Care).
RNA Interference
For siRNA studies, 1.106 ALL-SIL cells were electroporated in 400 mL serum-free RPMI 1640 medium supplemented with 4 mL of a
50 mM siRNA solution (final concentration of 200 nM) using the Gene Pulser Xcell system (Biorad) in 0,4 cm cuvettes. Immediately
after electroporation, cells were transferred to 2 mL pre-warmed RPMI 1640 medium supplemented with 20% fetal calf serum. For
antisense oligo knock-down experiments, 1.106 ALL-SIL cells were incubated with 5 mM or 10 mM antisense oligo in RPMI 1640 me-
dium supplemented with 20% fetal calf serum. The medium was changed every 48 hours, and fresh antisense oligo was added each
time. 1-2 days after siRNA electroporation or 2-6 days after antisense-oligo treatment, RNA was isolated using the Maxwell 16 LEV
Simply RNA purification kit (Promega) according to the instructions of the manufacturer.
Immunohistochemistry
Spleen tissue was fixed overnight in 10% neutral buffered formalin (Sigma) and then transferred to 50% ethanol. The samples were
processed for paraffin embedding (Thermo Scientific Excelsior AS Tissue Processor and HistoStar Embedding Workstation). Sec-
tions of 4 mm were mounted on Superfrost Plus Adhesion slides (Thermo Fisher Scientific) and stained with hematoxylin and eosin
(Diapath). For CD3 and Cre stainings, heat-induced antigen retrieval was performed, and the sections were subsequently blocked
with normal goat (Cre) or horse (CD3) serum. The sections were incubated overnight with the primary antibody at 4C and incubated
with the secondary antibody (conjugated with biotin-free HRP) for 30-45min at room temperature. Visualisation was performed using
a peroxidase substrate, and hematoxylin counterstaining was carried out.
In Vitro/Ex Vivo Inhibitor Treatments
For single-drug concentration studies, ALL-SIL, mouse leukemic cells, mouse leukemic cells transduced with an STAT5 N642H
expression construct, or patient-derived xenograft cells were incubated overnight with either the small molecule inhibitors (imatinib,
JQ1, ABT-199) or DMSO. To determine synergy between the different compounds, ALL-SIL, mouse leukemic cells or patient-derived
xenograft cells were seeded into 96-well plates and the compounds were added in a randomized fashion using a D300e digital
dispenser (Tecan). The DMSO concentration was normalized. Cell proliferation was measured after 48 hours using the ATPlite lumi-
nescence system (PerkinElmer) using a Victormultilabel plate reader. Data were analysed using the SynergyFinder software (Ianevski
et al., 2017).
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QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed using Prism software (Graphpad software, CA, USA). For analysis of the mouse data, survival
was calculated using the Kaplan-Meier method and two-sided p values were determined by the log-rank (Mantel Cox) test.
For qRT-PCR analyses, data are expressed as the mean ± standard deviation (SD). Comparisons between two groups were per-
formed by unpaired Student t tests.
To identify statistical significance of co-occurring ChIP peaks, the regulatory regions of the genome were defined by the H3K27ac
signal, and only the peaks within these regulatory regions were taken into account. To determine whether the overlap is greater than
expected by chance, a hypergeometric distribution was used to calculate the expected overlap and the p value.
DATA AND SOFTWARE AVAILABILITY
The RNA-seq, ChIP-seq and ATAC-seq data have been deposited in the Gene Expression Omnibus (GEO) database via accession
number GSE102209.
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